Inhibrx Biosciences, Inc. / Fundamentals
Income statement
- Net revenue
€1.21M - Cost of goods sold
€1.17M - Gross profit
€42.27K - SG&A expenses
€31.93M - R&D expenses
€113.35M - EBITDA
-€138.51M - D&A
€1.82M - EBIT
-€144.07M - Interest expenses
-€5.03M - EBT
-€141.20M - Tax expenses
€1.73K - Net income
-€141.20M
Cash flow statement
- Net deferred tax
€0.00 - Non-cash items
€21.26M - Changes in working capital
-€41.82M - Operating cash flow
-€120.63M - Capex
€244.98K - Other investing cash flow
€0.00 - Net investing cash flow
-€244.98K - Total cash dividends paid
€0.00 - Issuance of common stock
-€61.83M - Debt repayment
€0.00 - Other financing cash flow
€88.45M - Net financing cash flow
€88.45M - Foreign exchange effects
€0.00 - Net change in cash
-€34.76M - Cash at end of period
€160.93M - Free cash flow
-€120.39M
Balance sheet
- Cash and cash equivalents
€160.93M - Cash and short-term investments
€160.93M - Total receivables
€834.12K - Inventory
€0.00 - Other current assets
€5.55M - Total current assets
€167.31M - Property, plant & equipment
€9.79M - Goodwill
€0.00 - Intangible assets
€0.00 - Long-term investments
€0.00 - Other non-current assets
€5.87M - Total non-current assets
€15.66M - Total assets
€182.97M - Accounts payable
€7.15M - Short-term debt
€1.87M - Other current liabilities
€24.56M - Total current liabilities
€33.59M - Long-term debt
€9.21M - Deferred tax liabilities
€0.00 - Other non-current liabilities
€85.64M - Total non-current liabilities
€90.24M - Total liabilities
€123.83M - Common stock
€862.59 - Retained earnings
-€153.62M - Other equity
€0.00 - Total equity
€59.14M - Total liabilities and shareholders' equity
€182.97M
Company information
- Market capitalization
€178.17M - Employees
156 - Enterprise Value
€3.86M
Company ratios
- Gross margin
-
3.5% Much better than peer group: -90,014,765,319,336.9% - EBITDA margin
-
-11,469.3% Much better than peer group: -494,961,507,077,236.0% - EBIT margin
-
-11,929.6% Much better than peer group: -499,582,176,803,620.2% - EBT margin
-
-11,692.3% Much better than peer group: -498,989,333,759,836.7% - Net margin
-
-11,692.4% Much better than peer group: -498,989,333,761,126.5% - ROE
-
-238.8% Much worse than peer group: -31.3% - ROA
-
-77.2% Much worse than peer group: -41.7% - Asset turnover
-
0.7% Worse than peer group: 6.6% - FCF margin
-
-10,009.5% Much better than peer group: -415,767,343,690,617.7% - FCF yield
-67.8% - Efficiency ratio
11,569.3% - Net sales per employee
-
€7.74K - Net income per employee
-
-€905.13K